| Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States | | 2022 |
| Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry | | |
| Reduced CXCR4 expression in associated with extramedullary and predicts poor survival in newly diagnosed multiple myeloma | | |
| Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma | | 2022 |
| Myeloma precursor disease (MGUS) among rescue and recovery workers exposed to the World Trade Center disaster | | 2022 |
| Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study | | 2022 |
| Safety and tolerability of lenalidomide maintenance dosing in patients with multiple myeloma post-autologous stem cell transplant | Journal of Oncology Pharmacy Practice | |
| Real-world treatment patterns for patients with newly diagnosed multiple myeloma in Alberta, Canada | Leukemia and Lymphoma | |
| What’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma | Targeted Oncology | |
| Monoclonal gammopathy detection and current technologies | | 2022 |
| Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma | Blood Reviews | 2022 |
| Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients | Scientific Reports | 2022 |
| Convenient Access to Expert-Reviewed Health Information via an Alexa Voice Assistant Skill for Patients With Multiple Myeloma: Development Study | JMIR Cancer | 2022 |
| Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: a retro‐prospective observational study | European Journal of Haematology | |
| Converting a drug from off‐label to on‐label use: Government subsidies and patient welfare | Decision Sciences | |
| Melflufen for the treatment of multiple myeloma | Expert Review of Clinical Pharmacology | |
| Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma | Journal of Oncology Pharmacy Practice | |
| Suprasellar Plasmacytoma Leading to the Diagnosis of Multiple Myeloma | Cureus | 2022 |
| Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie’s choice for patients with relapsed refractory multiple myeloma | Expert Review of Hematology | |
| Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma. | Future Oncology | 2022 |
| Increasing genomic discovery in newly diagnosed multiple myeloma: defining disease biology and its correlation to risk. | Annals of Hematology | 2022 |
| Healthcare Costs of Multiple Myeloma Patients with Four or More Prior Lines of Therapy, Including Triple-Class Exposure in the United States. | Oncology and Therapy | 2022 |
| Diagnostic Applications of Nuclear Medicine: Multiple Myeloma | | 2022 |
| Hematological Diseases | | 2022 |
| Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma. | PLoS ONE | 2022 |
| Demographic differences among patients treated with chimeric antigen receptor T-cell therapy in the United States. | Cancer Medicine | 2022 |
| Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies. | Leukemia and Lymphoma | 2022 |
| Host-microbe interactions and outcomes in multiple myeloma and hematopoietic stem cell transplantation. | Cancer and Metastasis Reviews | 2022 |
| Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis. | Blood Cancer Journal | 2022 |
| Data_Sheet_1.pdf | | 2020 |
| Long term survival in multiple myeloma: a single institution experience in underprivileged circumstances. | Leukemia and Lymphoma | 2021 |
| Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma. | Supportive Care in Cancer | 2022 |
| Therapy-related myeloid neoplasms following treatment for multiple myeloma-a single center analysis. | Annals of Hematology | 2022 |
| Case Report: Cavernous Sinus Syndrome as the Initial Presentation of Multiple Myeloma | | 2022 |
| Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database. | Clinical Lymphoma, Myeloma and Leukemia | 2022 |
| Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs | | |
| A Review of Propylene Glycol-free Melphalan Conditioning for Hematopoietic Cell Transplantation for Multiple Myeloma and Light Chain Amyloidosis. | Transplantation and Cellular Therapy | 2022 |
| Myeloma-Related Hypercalcemia and Bone Disease | Contemporary Endocrinology | 2022 |
| Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients. | Leukemia | 2022 |
| Incidence of corneal adverse events in patients with multiple myeloma and their clinical and economic impact: a real-world retrospective cohort study. | Journal of Medical Economics | 2022 |
| Management of Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Novel Combination Therapies in Routine Clinical Practice in Germany. | Advances in Therapy | 2022 |
| Utilization of CRISPR-Mediated Tools for Studying Functional Genomics in Hematological Malignancies: An Overview on the Current Perspectives, Challenges, and Clinical Implications. | Frontiers in Genetics | 2021 |
| The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma. | Journal of Oncology Pharmacy Practice | 2022 |
| Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine. | Nature Reviews Clinical Oncology | 2022 |
| Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams. | Frontiers in Oncology | 2021 |
| An integrated approach to protein discovery and detection from complex biofluids | | |
| Isatuximab: Nursing Considerations for Use in the Treatment of Multiple Myeloma | Clinical Journal of Oncology Nursing | 2021 |
| Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study | BMC Cancer | 2021 |
| Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma | JCI Insight | 2021 |
| Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients | Hematology, Transfusion and Cell Therapy | 2021 |
| Factores pronósticos que afectan la supervivencia en el paciente con mieloma múltiple | | 2021 |
| Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy | Annals of Hematology | 2021 |
| Melflufen—A Novel Agent in the Treatment of Relapsed/Refractory Multiple Myeloma | Oncology & Hematology Review | 2020 |
| Patients with multiple myeloma referred for palliative care consultation: from retrospective analysis to future directions to improve clinical outcomes | Supportive Care in Cancer | 2021 |
| Survival Analysis of Multiple Myeloma Cancer (MMC) Using the Cox-Proportional Hazard Model | | 2020 |
| African American Patients With Multiple Myeloma: Optimizing Care to Decrease Racial Disparities | Clinical Journal of Oncology Nursing | 2020 |
| Immunotherapeutic Strategies for Multiple Myeloma | | 2020 |
| Novel pedigree analysis implicates DNA repair and chromatin remodeling in Multiple Myeloma risk | | |
| Bone Disorders in Cancer | | 2017 |
| Elotuzumab for Treatment of Multiple Myeloma (Literature Review) | Klinicheskaya Onkogematologiya/Clinical Oncohematology | 2016 |
| Treatment of elderly patients with myeloma | | 2015 |
| Early Combination Studies in Multiple Myeloma | | 2013 |
| Lifestyle considerations in multiple myeloma | Blood Cancer Journal | 2021 |
| Persistent fatigue among long-term non-Hodgkin lymphoma survivors | Leukemia and Lymphoma | 2021 |
| Healthcare Costs Incurred by Patients with Multiple Myeloma Following Triple Class Exposure (TCE) in the US | Oncology and Therapy | 2021 |
| Comorbidity and Personalized Treatment of Multiple Myeloma in Real Clinical Practice | Klinicheskaya Onkogematologiya/Clinical Oncohematology | 2020 |
| Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients' knowledge to manage adverse effects | PLoS ONE | 2020 |
| Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity | PLoS ONE | 2016 |
| Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk | PLoS Genetics | 2018 |
| Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents | Blood Advances | 2020 |
| Free light chains injure proximal tubule cells through the STAT1/HMGB1/TLR axis | JCI Insight | 2020 |
| Deep transcriptome profiling of multiple myeloma with quantitative measures using the SPECTRA approach | | |
| Mortality by a proxy performance status as defined by a claims-based measure for disability status in older patients with newly diagnosed multiple myeloma in the United States | Journal of Geriatric Oncology | 2019 |
| A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma | Leukemia and Lymphoma | 2021 |
| World Trade Center Survivor with Post Solid-Organ Transplant Plasma Cell Neoplasm. | Current Problems in Cancer Case Reports | 2021 |
| Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study | Clinical Lymphoma, Myeloma and Leukemia | 2021 |
| A Multicenter Study of Clinical Presentations and Outcomes of Multiple Myeloma in Pakistan: The Real-World Analysis in a Resource-Constrained Country. | Indian Journal of Hematology and Blood Transfusion | 2022 |
| Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma | Journal of Health Economics and Outcomes Research | 2021 |
| Front-line treatment patterns in multiple myeloma: An analysis of U.S.-based electronic health records from 2011 to 2019 | Cancer Medicine | 2021 |
| Multiple myeloma: a review of atypical imaging features and other distinct plasma cell disorders that demonstrate similar imaging features | Skeletal Radiology | 2022 |
| Role of Daratumumab in Combination With Standard Therapies in Patients With Relapsed and Refractory Multiple Myeloma | Cureus | 2021 |
| The role of bone-modifying agents in myeloma bone disease | JBMR Plus | 2021 |
| Patient-reported outcomes following autologous stem cell transplant for patients with multiple myeloma | EJHaem | 2021 |
| Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length | Leukemia | 2021 |
| Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma | American Journal of Hematology | 2021 |
| Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study | Leukemia and Lymphoma | 2021 |
| Novel Experimental Drugs for Treatment of Multiple Myeloma | Journal of Experimental Pharmacology | 2021 |
| Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma | Frontiers in Pharmacology | 2021 |
| Hospitalization at the end of life in patients with multiple myeloma | BMC Cancer | 2021 |
| The Lipoprotein Transport System in the Pathogenesis of Multiple Myeloma: Advances and Challenges | Frontiers in Oncology | 2021 |
| A Qualitative Study of the Experiences of Living With Multiple Myeloma | Oncology Nursing Forum | 2021 |
| Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma | JAMA Network Open | 2021 |
| Single-cell RNA sequencing: one step closer to the clinic | Nature Medicine | 2021 |
| Antibody-Based Treatment Approaches in Multiple Myeloma | Current Hematologic Malignancy Reports | 2021 |
| Game of Bones: How Myeloma Manipulates Its Microenvironment | Frontiers in Oncology | 2020 |
| Real-World Utilization and Safety of Daratumumab IV Rapid Infusions Administered in a Community Setting: A Retrospective Observational Study | Drugs - Real World Outcomes | 2021 |
| DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma | Seminars in Hematology | 2021 |
| A New Statistical Modeling Approach for Survival Analysis of Cancer Patients—Multiple Myeloma Cancer | Open Journal of Applied Sciences | 2021 |
| Impact of response to treatment in health-related quality of life patient-reported outcomes in elderly patients with relapsed multiple myeloma | Leukemia and Lymphoma | 2021 |
| Audit of the Prevalence of Noncorrelation of Immunofixation with Protein Electrophoresis and Serum Free Light Chain Assays in Multiple Myeloma in a Tertiary Cancer Care Center | Indian Journal of Clinical Biochemistry | 2021 |
| Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial | British Journal of Haematology | 2021 |
| Discharge status and post-discharge healthcare costs after skeletal-related event hospitalizations among medicare patients with bone metastatic solid tumors or multiple myeloma | Journal of Bone Oncology | 2021 |
| Burden of Treatment Among Older Adults With Newly Diagnosed Multiple Myeloma | Clinical Lymphoma, Myeloma and Leukemia | 2021 |
| Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011-2019 oncology clinic electronic health record data | Leukemia and Lymphoma | 2021 |
| Identification and characterization of deschloro-chlorothricin obtained from a large natural product library targeting aurora A kinase in multiple myeloma | Investigational New Drugs | 2021 |
| Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients | Journal of Clinical Pharmacology | 2021 |
| Approaching the first relapse after autologous transplant in multiple myeloma | Advances in Cell and Gene Therapy | 2021 |
| Symptom burden and its functional impact in patients with "symptomatic" relapsed or refractory multiple myeloma | Supportive Care in Cancer | 2021 |
| Prevalence and Incidence of Multiple Myeloma in Urban Area in China: A National Population-Based Analysis | Frontiers in Oncology | 2019 |
| US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma | ClinicoEconomics and Outcomes Research | 2020 |
| Management of newly diagnosed transplant ineligible multiple myeloma | Leukemia and Lymphoma | 2020 |
| Extramedullary Disease in Multiple Myeloma | Current Hematologic Malignancy Reports | 2020 |
| Supportive Care in Multiple Myeloma | Current Hematologic Malignancy Reports | 2020 |
| Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis | Advances in Therapy | 2020 |
| New drugs in early development for treating multiple myeloma: all that glitters is not gold | Expert Opinion on Investigational Drugs | 2020 |
| A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma | Leukemia | 2020 |
| The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied? | Blood Cancer Journal | 2020 |
| Characterizing Pain Experiences: African American Patients With Multiple Myeloma Taking Around-the-Clock Opioids | Clinical Journal of Oncology Nursing | 2020 |
| Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma | Hematology, Transfusion and Cell Therapy | 2021 |
| Erstlinientherapie von Patienten mit multiplem Myelom | InFo Hämatologie + Onkologie | 2020 |
| The clinical and pathological features of plasma cell myeloma post solid organ transplantation | American Journal of Hematology | 2020 |
| Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma | Expert Review of Hematology | 2020 |
| Current developments in the combination therapy of relapsed/refractory multiple myeloma | Expert Review of Anticancer Therapy | 2020 |
| Ixazomib-associated cardiovascular adverse events in multiple myeloma: a systematic review and meta-analysis | Drug and Chemical Toxicology | 2020 |
| Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study | Ophthalmology and Therapy | 2020 |
| Discovery and validation of surface -glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets | | 2020 |
| Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment | Frontiers in Oncology | 2020 |
| Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma | BMC Cancer | 2020 |
| B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis | European Journal of Haematology | 2020 |
| Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front-line regimens using the SEER-Medicare data | Cancer Medicine | 2020 |
| How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review | Quality of Life Research | 2020 |
| Depressive symptoms, mental health-related quality of life, and survival among older patients with multiple myeloma | Supportive Care in Cancer | 2020 |
| Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up | Biology of Blood and Marrow Transplantation | 2020 |
| Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data | European Journal of Health Economics | 2020 |
| Connect MM Registry as a national reference for United States multiple myeloma patients | Cancer Medicine | 2020 |
| Physical activity and health-related quality of life in multiple myeloma survivors: the PROFILES registry | BMJ Supportive and Palliative Care | 2020 |
| Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma | PharmacoEconomics - Open | 2020 |
| Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data | Quality of Life Research | 2020 |
| Cutaneous light chain amyloidosis with multiple myeloma: A concise review | Hematology/ Oncology and Stem Cell Therapy | 2019 |
| Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities | Biology of Blood and Marrow Transplantation | 2019 |
| Multiple myeloma bone lesions in skeletal remains: Report of two known cases from the 20th century CAL Milano Cemetery Skeletal Collection | International Journal of Osteoarchaeology | 2019 |
| Overexpression of HIF-1α contributes to melphalan resistance in multiple myeloma cells by activation of ERK1/2, Akt, and NF-κB | Laboratory Investigation | 2019 |
| Rare case of non-producer variant of plasma cell dyscrasias with circulating plasma cells | BMJ Case Reports | 2019 |
| Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis | The Cochrane Library | 2019 |
| Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis | Blood Advances | 2019 |
| The pharmacologic management of multiple myeloma in older adults | Expert Opinion on Pharmacotherapy | 2019 |
| Management of cardiovascular risk in patients with multiple myeloma | Blood Cancer Journal | 2019 |
| Classification of Plasma Cell Disorders by 21 Tesla Fourier Transform Ion Cyclotron Resonance Top-Down and Middle-Down MS/MS Analysis of Monoclonal Immunoglobulin Light Chains in Human Serum | Analytical Chemistry | 2019 |
| The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management | Frontiers in Immunology | 2019 |
| Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries | Annals of Hematology | 2019 |
